BioInsights - Predicting patient response to immune targeted therapies via interrogation of the TME
Oct
12
2022
On demand

Predicting patient response to immune targeted therapies via interrogation of the TME

Sponsor
Predicting patient response to immune targeted therapies via interrogation of the TME

More accurately predicting which patients will benefit from immune targeted therapies, including checkpoint inhibitors, remains a crucial goal for the I–O field.

This webinar will provide an overview of an RNA-based investigational tumor microenvironment (TME) panel to better interrogate tumor biology and support multiple oncology therapeutics – particularly immune checkpoint inhibitors and anti-angiogenic agents – across a range of tumor types.

New translational data on predicting benefit from maintenance durvalumab after first-line chemotherapy in esophagogastric adenocarcinoma will be discussed, along with the potential for companion diagnostic development in support of clinical development.

  • The broad clinical and research applications of an RNA-based TME assay for I–O applications
  • How interrogation of the TME via RNA signatures can improve the identification of patients who might benefit from multiple oncology therapeutics, particularly immune checkpoint inhibitors and anti-angiogenic agents
  • Future development of the Xerna TME Panel as an RUO, CTA and CDx assay platform

Mark Uhlik, PhD

Vice President, Head of Research and Biomarker Discovery, OncXerna Therapeutics

Mark is a seasoned leader in translational oncology and drug discovery/development with over 18 years of experience in the pharmaceutical industry. Mark earned his B.S. in Microbiology from Colorado State University and his Ph.D. in Microbiology and Immunology at Pennsylvania State University College of Medicine. He performed post-doctoral work at University of Colorado Health Sciences Center and at University of North Carolina School of Medicine. Mark has authored over 35 peer-reviewed publications in addition to book chapters and patents.

Dr Caroline Fong

Specialty Registrar in Medical Oncology, Royal Marsden NHS Foundation Trust

Caroline is a Medical Oncology Registrar at the Royal Marsden Hospital in London. She has recently completed a four-year Clinical Research Fellowship with the Gastrointestinal and Lymphoma Unit at the Royal Marsden, where she was the Trial Physician and a Co-Investigator of the PLATFORM study, an academic, multi-centre, randomised phase II clinical trial assessing the role of maintenance therapies in advanced oesophago-gastric cancers. She is currently working towards a thesis centred on predictive biomarkers in oesophago-gastric cancers.

SPEAKERS

Mark  Uhlik, PhD
Mark Uhlik, PhD
Vice President, Head of Research and Biomarker Discovery, OncXerna Therapeutics
Dr Caroline Fong
Dr Caroline Fong
Specialty Registrar in Medical Oncology, Royal Marsden NHS Foundation Trust

You might also like